Skip to main content

It's our mission to help you get NULIBRY to your patients when they need it—because immediate action is critical

Sentynl Cares | NULIBRY Access and Support program gives you and your patients support during the benefits verification and prescription fulfillment process

Sentynl Cares access support program logo

Sentynl Cares | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

If you have a suspected or confirmed patient with MoCD Type A, please call Sentynl Cares at
1-888-251-2800

If you are a hospital or healthcare organization wanting to acquire NULIBRY, please call Sentynl Cares | NULIBRY at 1-888-251-2800.

If you are a caregiver and have any questions about NULIBRY or would like information about affordability options, please call Sentynl Cares | NULIBRY at 1-888-251-2800.

The Sentynl Cares | NULIBRY Acute Site QuickStart Program is designed to rapidly provide free drug to patients in the acute care setting with a newly confirmed or suspected diagnosis of MoCD Type A.

Requests can be processed 24 hours a day, 7 days a week, and drug delivered within 24 hours in most cases.

Patient Affordability Options

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

SIDE EFFECTS

The most common side effects in NULIBRY-treated patients were infusion catheter–related complications, pyrexia (fever), viral infection, pneumonia, otitis media (ear infection), vomiting, cough/sneezing, viral upper respiratory infection (common cold/flu-like infection), gastroenteritis (stomach flu-like symptoms), diarrhea, and bacteremia (bacteria in the blood). Side effects for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.

 

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.